Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 43Lymphoma, Large B-Cell, Diffuse 35Burkitt Lymphoma 33Lymphoma 26Lymphoma, Follicular 16Rhabdomyosarcoma 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, B-Cell 12Neuroblastoma 10Medulloblastoma 10Lymphoma, Non-Hodgkin 10Leukemia 10Sarcoma, Ewing 9Leukemia, Biphenotypic, Acute 9Recurrence 8Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 8Neoplasms 8Lymphoma, T-Cell, Peripheral 8Lymphoma, Mantle-Cell 7Lymphoma, B-Cell, Marginal Zone 7Hodgkin Disease 7Wilms Tumor 5Sarcoma 5Retinoblastoma 5Osteosarcoma 4Lymphoproliferative Disorders 4Lymphoma, T-Cell 4Leukemia, Lymphocytic, Chronic, B-Cell 4Ganglioneuroblastoma 4Down Syndrome 4

Interventions

prednylidene 1etoposide phosphate 1deltacortene 1Vincristine 1Vinblastine 1Specimen Handling 1Procarbazine 1Prednisone 1Prednisolone 1Nivolumab 1Methylprednisolone 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Etoposide 1Doxorubicin 1Dacarbazine 1Cyclophosphamide 1Brentuximab Vedotin 1Bleomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 × Vincristine × 1 year × Clear all
NCT05675410 2026-06-03

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

National Cancer Institute (NCI)

Phase 3 Recruiting
1,875 enrolled
Lymphoid

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡